“We are pleased with our accomplishments in 2024, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty, CEO of the company. “Looking ahead, we are excited about the opportunities for growth in 2025 and beyond, as we continue to advance our proprietary drug development program to deliver more life-saving medicines to the market.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBFM: